Abstract: Sequences that enhance permeation of agents into cells and/or across the blood brain barrier, compositions comprising the sequences, and methods of use thereof.

Abstract: The present application relates to sequences that enhance permeation of immunotherapy agents across the blood brain barrier (BBB), compositions comprising the sequences, and methods of use thereof to treat brain cancer, e.g., glioblastoma (GBM). Further disclosed are a number of potential targeting peptide sequences identified that enhance permeation through the BBB, when inserted into the capsid of an adeno-associated virus (AAV).

Abstract: Described herein are compositions and methods for tissue-targeted expression of therapeutic genes, using AAV expression vectors that reduce the risk of toxicity associated with AAV gene therapy in the CNS by de-targeting the vulnerable neurons cells including the DRG cells on gene expression, and de-targeting the liver, a major suspect for over-expression in the periphery.

Abstract: Sequences that enhance permeation of agents into cells and/or across the blood brain barrier, compositions comprising the sequences, and methods of use thereof.

Abstract: Disclosed herein are methods for promoting neuronal outgrowth in a subject with a neuronal lesion in their CNS by administering effective amounts of a pro-regenerative OPN fragment, optionally with IGF1 and/or BDNF. A voltage gated potassium channel blocker can also be administered. Pharmaceutical compositions, devices for administration, and kits are also disclosed.

Abstract: Sequences that enhance permeation of agents into cells and/or across the blood brain barrier, compositions comprising the sequences, and methods of use thereof.

Abstract: The present invention is based on the development of artificial targeting sequences that enhance permeation of agents into cells and across the blood brain barrier, compositions comprising the sequences, and methods of use thereof. Provided herein is an AAV comprising a capsid protein comprising a targeting sequence and a transgene, preferably a therapeutic or diagnostic transgene. Further, provided herein are methods of delivering a transgene to a cell, the method comprising contacting the cell with an AAV or fusion protein described herein.

Abstract: Disclosed herein are methods for promoting neuronal outgrowth in a subject with a neuronal lesion in their CNS by administering effective amounts of a pro-regenerative OPN fragment, optionally with IGF1 and/or BDNF. A voltage gated potassium channel blocker can also be administered. Pharmaceutical compositions, devices for administration, and kits are also disclosed.